Effect of combined oral contraceptives and cyperoterone acetate-ethinyl estradiol combination on metabolic syndrome in polycystic ovarian syndrome (PCOS)
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 6, Pages 1571-1578
AbstractIntroduction: Polycystic ovarian syndrome (PCOS) is an endocrine disorder with multiple etiology and affecting women in reproductive age group. It has become a major problem in modern era and requires a multimodality of treatment.
Material and methods: The study was conducted on 100 PCOS patients attending PGIMS, Rohtak outpatient department to compare the efficacy of combined oral contraceptives (COCs) and cyperoterone acetate-ethinyl estradiol (CPA-EE) combination on metabolic parameters. This was a prospective interventional study conducted for one and half year. Patients were followed at one, three and six months of treatment and comparison was made from baseline to six months of treatment.
Results: Both the drugs did not change the waist circumference and blood pressures of the patients, while improved fasting blood sugars from third month of treatment. COCs were found to deteriorate the sugar levels more significantly when compared to CPA-EE. Both the drugs significantly derange the triglyceride and high density lipoprotein levels, CPA-EE being more than COCs.
Conclusion: Any of the drug can be used in the treatment of PCOS patients but with caution in diabetic and hyperlipidemic patients.
Keywords: Polycystic ovarian syndrome (PCOS), combined oral contraceptives (COCs), cyperoterone acetate-ethinyl estradiol (CPA-EE), metabolic syndrome, diabetes, hyperlipidemia.
Synopsis: Both the drugs are equally effective in improving the metabolic parameters but derange the blood sugars and lipid profile
- Article View: 16
- PDF Download: 16